Abstract
Background:
S-1 is a new anti-cancer drug. It was reported that the response rate of patients with gastric cancer treated with this drug is 49%. We reported that the serum and intraabdominal concentrations of 5-FU after the administration of S-1 are almost the same. This retrospective study was undertaken to examine the clinical efficacy of S-1 in patients with advanced gastric cancer and positive cytology.
Method:
Between 1995 and 1999, 26 patients with gastric cancer and positive cytology diagnosed during the operation were surgically treated. Fifteen underwent total, distal or proximal gastrectomy with D2 lymphadenectomy and 11 underwent simple laparotomy or bypass surgery because of peritoneal dissemination. These patients were divided into the S-1 group and the 5-FU group. Survival rate and median survival time (MST) were evaluated and compared between the two groups.
Results:
The MST of the S-1 group was 579 days and that of the 5-FU group was 211 days. Among the 15 resected cases, the MST of those administered S-1 was 768 days and that of patients administered 5-FU was 215 days. The survival rate of the S-1 group was significantly higher than that of the 5-FU group (p=0.0023).
Conclusion:
We conclude that S-1 is an effective adjuvant anti-cancer drug for patients with advanced gastric cancer and positive cytology.
